These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 16312044

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Tumor-mediated down-regulation of MHC class II in DC development is attributable to the epigenetic control of the CIITA type I promoter.
    Choi YE, Yu HN, Yoon CH, Bae YS.
    Eur J Immunol; 2009 Mar; 39(3):858-68. PubMed ID: 19224634
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Downregulation of CIITA function by protein kinase a (PKA)-mediated phosphorylation: mechanism of prostaglandin E, cyclic AMP, and PKA inhibition of class II major histocompatibility complex expression in monocytic lines.
    Li G, Harton JA, Zhu X, Ting JP.
    Mol Cell Biol; 2001 Jul; 21(14):4626-35. PubMed ID: 11416140
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Revisiting the specificity of the MHC class II transactivator CIITA in vivo.
    Otten LA, Leibundgut-Landmann S, Huarte J, Kos-Braun IC, Lavanchy C, Barras E, Borisch B, Steimle V, Acha-Orbea H, Reith W.
    Eur J Immunol; 2006 Jun; 36(6):1548-58. PubMed ID: 16703565
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Detection of aberrant transcription of major histocompatibility complex class II antigen presentation genes in chronic lymphocytic leukaemia identifies HLA-DOA mRNA as a prognostic factor for survival.
    Souwer Y, Chamuleau ME, van de Loosdrecht AA, Tolosa E, Jorritsma T, Muris JJ, Dinnissen-van Poppel MJ, Snel SN, van de Corput L, Ossenkoppele GJ, Meijer CJ, Neefjes JJ, Marieke van Ham S.
    Br J Haematol; 2009 May; 145(3):334-43. PubMed ID: 19245431
    [Abstract] [Full Text] [Related]

  • 35. MHC class II expression is differentially regulated in plasmacytoid and conventional dendritic cells.
    LeibundGut-Landmann S, Waldburger JM, Reis e Sousa C, Acha-Orbea H, Reith W.
    Nat Immunol; 2004 Sep; 5(9):899-908. PubMed ID: 15322541
    [Abstract] [Full Text] [Related]

  • 36. Mini-review: Specificity and expression of CIITA, the master regulator of MHC class II genes.
    LeibundGut-Landmann S, Waldburger JM, Krawczyk M, Otten LA, Suter T, Fontana A, Acha-Orbea H, Reith W.
    Eur J Immunol; 2004 Jun; 34(6):1513-25. PubMed ID: 15162420
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. N-terminal destruction signals lead to rapid degradation of the major histocompatibility complex class II transactivator CIITA.
    Schnappauf F, Hake SB, Camacho Carvajal MM, Bontron S, Lisowska-Grospierre B, Steimle V.
    Eur J Immunol; 2003 Aug; 33(8):2337-47. PubMed ID: 12884309
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.